No profile data available.
RenovoRx, Inc. (RNXT) is a healthcare company in the IV treatment equipment industry, based in Mountain View, United States, with about 17 full-time employees.
It reported revenue of $43,000 for fiscal year 2024, and net income of -$8.81 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $266,000. Its market capitalization was $57.77 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
RenovoRx reported $43,000 in revenue for fiscal year 2024. In Q3 2025 revenue was $266,000.
$57.77 million as of October 9, 2026.
Listed companies of a similar size in the same industry (IV treatment equipment) include Delcath Systems, Inc. (DCTH), TriSalus Life Sciences, Inc. (TLSI), Koru Medical Systems, Inc. (KRMD), Modular Medical, Inc. (MODD).